Dianthus Therapeutics disclosed successful Phase 2 trial outcomes for claseprubart, a selective complement inhibitor targeting generalized myasthenia gravis. The antibody met multiple efficacy endpoints, demonstrating symptom improvement with an acceptable safety profile. Dianthus is advancing this candidate as a potential new therapy for neuromuscular autoimmune diseases. These results underpin imminent plans for pivotal studies aiming to establish market approval and broaden the treatment options for patients suffering from this debilitating disorder.